We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.
The TGF-β superfamily comprises multifunctional signaling proteins and key regulators of homeostasis and repair throughout the body.1 Dysfunction of TGF-β superfamily members has been implicated in cancer and other pathological conditions. Ligands in this superfamily mediate their diverse effects by inducing distinct combinations of type I and II receptors and their downstream effectors—Smad proteins.1
Preclinical studies have shown that Smad2/3 signaling, mediated by members of the TGF-β superfamily, may have effects on erythroid precursors2-4 and is involved in regulating late-stage erythropoiesis.5-7 Defective late-stage erythropoiesis results in impaired red blood cell maturation, leading to anemia and contributing to iron overload.8,9 However, the specific roles of Smad2/3 signaling in red blood cell production have not been fully elucidated. In a mouse model of β-thalassemia, inhibition of abnormally elevated Smad2/3 signaling improved hematology parameters associated with ineffective erythropoiesis.10
Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.